Dr. Leslie Discusses Duvelisib in Follicular Lymphoma

Lori A. Leslie, MD
Published: Monday, Apr 09, 2018



Lori A. Leslie, MD, lymphoma attending, John Theurer Cancer Center, discusses the role of duvelisib in the treatment of patients with follicular lymphoma.

PI3K is an important target in follicular lymphoma, and duvelisib has shown efficacy in the relapsed/refractory setting. However, it is not without toxicity, Leslie says. Duvelisib and some of the other targeted agents, though effective, have a similar toxicity profile. Some newer agents approved in the relapsed/refractory setting, like copanlisib (Aliqopa), have a similar efficacy without the added toxicity of some of the previous generation PI3K inhibitors.

Umbralisib (TGR-1202) is another efficacious and tolerable PI3K-delta inhibitor that likely will be approved for follicular lymphoma, Leslie explains. Developing better prognostic indices to predict poor outcomes to upfront chemoimmunotherapy will help physicians better use risk-adapted approaches to combine novel agents with standard-of-care backbones. Hopefully, the field will be able to move towards a chemotherapy-free approach, Leslie says.
 


Lori A. Leslie, MD, lymphoma attending, John Theurer Cancer Center, discusses the role of duvelisib in the treatment of patients with follicular lymphoma.

PI3K is an important target in follicular lymphoma, and duvelisib has shown efficacy in the relapsed/refractory setting. However, it is not without toxicity, Leslie says. Duvelisib and some of the other targeted agents, though effective, have a similar toxicity profile. Some newer agents approved in the relapsed/refractory setting, like copanlisib (Aliqopa), have a similar efficacy without the added toxicity of some of the previous generation PI3K inhibitors.

Umbralisib (TGR-1202) is another efficacious and tolerable PI3K-delta inhibitor that likely will be approved for follicular lymphoma, Leslie explains. Developing better prognostic indices to predict poor outcomes to upfront chemoimmunotherapy will help physicians better use risk-adapted approaches to combine novel agents with standard-of-care backbones. Hopefully, the field will be able to move towards a chemotherapy-free approach, Leslie says.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Oncology Best Practice™: Choosing Therapies for Patients with EGFR-mutant Lung Cancers: More Options... More Decisions... Better OutcomesApr 27, 20182.0
Community Practice Connections™: 21st Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and MyelomaApr 27, 20182.0
Publication Bottom Border
Border Publication
x